Daiichi, GE Healthcare to collaborate on non-nuclear contrast media R&D
Daiichi Pharmaceutical Co., Ltd. and GE Healthcare have executed a collaboration agreement for the research and development of non-nuclear contrast media. Since Daiichi launched Omnipaque in 1987, a contrast media for x-ray and CT exams, Daiichi has marketed Omniscan, MRI contrast media (launched in 1996) and Visipaque, an x-ray contrast media (launched in 2000) in Japan.
In addition to these products licensed to GE Healthcare, the two companies have collaborated on the research and development of non-nuclear contrast media to obtain development candidates since 1988. As a result, Daiichi submitted Sonazoid, an ultrasound contrast media in May 2004 for regulatory approval in Japan.
In addition to these products licensed to GE Healthcare, the two companies have collaborated on the research and development of non-nuclear contrast media to obtain development candidates since 1988. As a result, Daiichi submitted Sonazoid, an ultrasound contrast media in May 2004 for regulatory approval in Japan.